Cognitive improvement during Tolcapone treatment in Parkinson's disease.
about
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's diseaseCatechol-O-methyltransferase polymorphisms and some implications for cognitive therapeuticsTolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's diseaseModulation of hippocampal dopamine metabolism and hippocampal-dependent cognitive function by catechol-O-methyltransferase inhibitionBiological and social influences on cognitive control processes dependent on prefrontal cortexMolecular targets for treating cognitive dysfunction in schizophrenia.Catechol-O-methyltransferase Val 158 Met polymorphism and antisaccade eye movements in schizophreniaThe endophenotype concept in psychiatric genetics.Influence of the COMT val(108/158)met polymorphism on continuous performance task indices.Effect of tolcapone on brain activity during a variable attentional control task: a double-blind, placebo-controlled, counter-balanced trial in healthy volunteersTreatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.Tolcapone improves cognition and cortical information processing in normal human subjects.Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine.COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibitionThe catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes.Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs.Consequences of variations in genes that affect dopamine in prefrontal cortexIs COMT a susceptibility gene for schizophrenia?Polymorphisms in genes modulating the dopamine system: do they inf luence outcome and response to medication after traumatic brain injury?Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotypeTolcapone addition improves Parkinson's disease associated nonmotor symptoms.The biochemical womb of schizophrenia: A review.Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.Examining the effects of dopamine genes on verbal IQ within and between families.Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.Effects of COMT genotype and tolcapone on lapses of sustained attention after sleep deprivation in healthy young men.Safinamide: an add-on treatment for managing Parkinson's disease.
P2860
Q24245911-B58643B1-9EFD-4399-A7F6-6681D9D571DAQ24608073-EEC88BC4-DB96-43A2-A69C-03CB3C85CE29Q24657680-C3ECF106-F81F-4272-9924-A0A69B0BDCC9Q28580165-EAD3086D-222D-4F3B-B869-289DBD1C5989Q29397599-F6B63EC0-07F1-4EB4-95C7-A445172537D3Q30491310-E55B2251-9B73-470D-B893-74B672AEA6CBQ33566069-52DB3701-AF11-49C9-8FBC-F8E16ABC1ACEQ33693915-1AD71F45-B0F3-48F4-A420-4F4898E3BC61Q34005917-5305B2DB-1CDD-448B-A249-FBB79BA919F0Q34055505-69CC8603-DED2-464B-9BDE-71C030D0850EQ34338202-2BE50942-4CB3-45CA-BA76-E8B8E2B03DF7Q34576438-9C21BAB7-5E5B-4DD1-8534-8760E1C061E6Q35023131-8A051CD6-3236-4572-BBB2-A87384F8052FQ35859549-AF577D7D-F962-4C7D-B5B0-26DC931F1437Q35860569-B7A63BD0-8841-4CAF-827C-9509F3E1BE3AQ36401912-8EA9174B-1DE3-4CA1-BEEB-88ED5755DE6DQ36453838-66A7802D-EE8B-46CC-BB7A-7FECA41D3893Q36782538-4FB8E3A0-3B9F-4B52-8111-CD95FF31CF5FQ37374171-14FFCFD2-7D90-4748-BBE9-2CDC1D54778AQ37497959-A368EED9-E6FC-4797-B04B-0B0C0ED93854Q37599580-3034D749-89DB-4164-A0D7-F25CFA594718Q38056122-752B0E84-04C8-46E7-A330-A05D3E809D7FQ38817972-817B1345-66B4-4AE7-8913-87D14439C904Q39325939-127D4E4B-5659-42BF-96FB-537D0B3DBADAQ39565000-8EF7B1DB-FC49-4A71-B0B4-FA1925F2E2A0Q42429830-389A5915-489E-452C-A586-B72C38C5EC31Q42536582-E125063C-2441-4A3E-B11D-1EA6E1362778Q52689102-1284E6BB-4C02-494F-8F9D-E7921597A3A3Q52804779-7F4A7B23-EE12-4716-AE90-E4CA11B8213B
P2860
Cognitive improvement during Tolcapone treatment in Parkinson's disease.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Cognitive improvement during Tolcapone treatment in Parkinson's disease.
@en
Cognitive improvement during Tolcapone treatment in Parkinson's disease.
@nl
type
label
Cognitive improvement during Tolcapone treatment in Parkinson's disease.
@en
Cognitive improvement during Tolcapone treatment in Parkinson's disease.
@nl
prefLabel
Cognitive improvement during Tolcapone treatment in Parkinson's disease.
@en
Cognitive improvement during Tolcapone treatment in Parkinson's disease.
@nl
P50
P356
P1476
Cognitive improvement during Tolcapone treatment in Parkinson's disease.
@en
P2888
P304
P356
10.1007/BF01285556
P4011
70e072a6c1047c3b10495bf0f54f1eb7b950bab0
P577
1997-01-01T00:00:00Z